Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease

Table 2 Biological, pharmacokinetic, clinical and endoscopic data at baseline and during follow up

	Baseline, n = 62	Week 14, n = 59	P value (week 14- baseline)	Week 46, n = 56	P value (week 46- baseline)
CDAI, median (IQR)	201 (114-236)	60 (28-94)	P < 0.001	53 (26-94)	P < 0.001
CDEIS, median (IQR)	6.7 (5-11.3)	3.2 (0.8-5)	P < 0.001	3.0 (0.2-4.4)	P < 0.001
CRP mg/dL, median (IQR)	0.66 (0,16-1.72)	0.2 (0.03-0.71)	P = 0.125	0.19 (0.03-0.76)	P < 0.05
Hemoglobin g/L, median (IQR)	127 (113-140)	135 (121-141)	P < 0.05	134 (123-143)	P < 0.05
Albumin g/L, median (IQR)	41 (40-43)	43 (40-45)	P < 0.05	43 (40-45)	P < 0.05
Serum TNF-alpha pg/mL, median (IQR)	5.5 (3.3-8)	20 (11-36)	P < 0.001	17 (8.25-30)	P < 0.001
Fecal Calprotectin μg/g, median (IQR)	1044 (685-1800)	610 (209-1646)	P < 0.05	940 (233-1747)	P < 0.05
Infliximab μg/mL, median (IQR)	0 (0-0)	3.1 (1.2-5.6)	P < 0.001	1.8 (1-6.6)	P < 0.001
ATIs, % patients (n)	8 (5/62)	3 (1/34)	P = 0.327	13 (4/32)	P = 0.230
Adalimumab μg/mL, median (IQR)	0 (0-0)	8.9 (5.6-12)	P < 0.001	9.9 (7-12)	P < 0.001
ATAs, % patients (n/total)	10 (6/62)	0 (0/25)	P = 0.117	4.1 (1/24)	P = 0.408

IQR: Interquartile range; CRP= C reactive protein; TNF-alpha: Tumor necrosis factor alpha; ATIs: Anti-infliximab antibodies; ATAs: Anti-adalimumab antibodies; CDAI: Crohn’s Disease Activity Index; CDEIS: Crohn’s Disease Endoscopic Index of Severity.